Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Japan’s 25 Major Drug Makers Log Contrasting Domestic Biz Results on Varying New Product Performances
November 14, 2012
-
REGULATORY Health Coverage for OTC-Like Drugs Up for Review Yet Again
November 13, 2012
-
REGULATORY Zoledronic Acid, Sildenafil Subject to Pilot Study on Generic RMPs
November 12, 2012
-
BUSINESS Time Will Tell Whether Once-monthly Products Ultimately Dominate or Merely Provide Another Option in the BP Market
November 12, 2012
-
BUSINESS Four Companies Discontinue Marketing Atelec Generics Due to Halt in Supplies of Bulk Drug Substance
November 9, 2012
-
REGULATORY Drug Makers Invited to Join in Intractable Disease Drug Discovery Research Using iPS Cells from This Fiscal Year
November 8, 2012
-
BUSINESS Takeda to Buy Envoy of US to Reinforce Drug Discovery Prowess
November 7, 2012
-
BUSINESS Abbott Japan Spins Off New Drug Biz, Establishes New Firm “AbbVie”
November 6, 2012
-
BUSINESS Sawai’s Status Improved Within Mediceo by Utilizing ARs
November 6, 2012
-
BUSINESS Domestic Drug Makers’ Major Products See Sharp Declines in 1st Half; Sales of Aricept, Lipitor Down 30%
November 5, 2012
-
BUSINESS “Lecture Meeting Fever” as Companies Seek New Ways to Interact with Doctors Under Tougher Restrictions on Settai
November 5, 2012
-
BUSINESS Sales Target for Prasugrel Achievable Despite Add’l Indication Dropped: Daiichi Sankyo Pres. Nakayama
November 2, 2012
-
BUSINESS Takeda’s Japan Sales Ratio Likely to Fall to Mid-30% Range: President Hasegawa
November 1, 2012
-
BUSINESS Mochida, MTPC See Signs of Sales Growth for Lexapro after Lifting of Long-Term Prescription Ban
October 31, 2012
-
BUSINESS Shionogi to Take Part in GSK-Pfizer JV, Realigns Strategy in HIV Field
October 30, 2012
-
BUSINESS Chugai to License SGLT-2 Inhibitor to Kowa, Sanofi
October 29, 2012
-
BUSINESS Janssen’s New MR Training System Aims to Produce “Consulting MRs”
October 29, 2012
-
REGULATORY MHLW to Initially Limit Number of Stores to Offer Epadel OTC
October 26, 2012
-
BUSINESS “Changing Way of Thinking Necessary among Industry, Government, Academia for Promotion of Drug Discovery”: AZ Chairman Kato
October 25, 2012
-
BUSINESS Santen Going on Offensive in Growth Fields in Ophthalmology
October 24, 2012
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…